US EditionShareholders Who Lost Money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein - PepGen (NASDAQ:PEPG)
- On May 28, 2025, PepGen Inc. announced it was ending its Duchenne muscular dystrophy programs after PGN-EDO51 failed to produce the expected increase in dystrophin in the CONNECT1 trial.
- This decision followed earlier events in 2024 and 2025, including FDA clinical holds and safety concerns that emerged after PepGen initially reported positive but ultimately disappointing clinical data from the CONNECT1 trial.
- PepGen's initial July 30, 2024, press release claimed PGN-EDO51 achieved a mean dystrophin level of 0.61%, but analysts noted this was below PepGen's 1% target and raised questions about the drug’s efficacy and safety.
- Following the FDA's clinical hold on CONNECT2 in December 2024 and subsequent voluntary study pause in March 2025, PepGen's stock price declined significantly, including a 32.69% drop on July 31, 2024, and an 18.86% drop on March 4, 2025.
- A securities class action has been filed against PepGen and some of its top executives, accusing them of providing false or misleading information regarding the clinical performance, regulatory outlook, and commercial potential of PGN-EDO51. The deadline to seek lead plaintiff status in the case is August 11, 2025.
64 Articles
64 Articles
Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein - PepGen (NASDAQ:PEPG)
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- June 11, 2025 - Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of PepGen Inc. (NASDAQ:PEPG) between March 7, 2024 and March 3, 2025, inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares of PepGen should contact the Firm prior to the August …
PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should ...
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased
#PepGen Inc. Legal and Strategic Crossroads Amidst Market Turbulence,
' for CSIMarket.com ' PepGen Inc.: Navigating a Strategic Pivot Amidst Legal and Market Challenges' PepGen Inc. (NASDAQ: PEPG), a biopharmaceutical company, currently finds itself at a crucial juncture. Recently, the law firm Bragar Eagel & Squire, P.C. announced a class action lawsuit against the company, urging investors to contact them for possible claims. This development comes against a backdrop of significant strategic and market-related c…
Coverage Details
Bias Distribution
- 69% of the sources are Center
To view factuality data please Upgrade to Premium
